Forbes -- At Merck’s annual meeting earlier this week, much of the focus was on two clot-preventing drugs the company is developing: vorapaxar, which it acquired as part of its merger with Schering-Plough, and betrixiban, which Merck licensed from Portola, a smaller drug firm.
